News · 26 weeks56+100%
2026-03-012026-08-23
Mix2390d
- Insider11(48%)
- SEC Filings7(30%)
- Other4(17%)
- Earnings1(4%)
Latest news
25 items- SECSEC Form D filed by Femasys Inc.D - FEMASYS INC (0001339005) (Filer)
- PRFemasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®ATLANTA, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that the U.S. Food and Drug Administration has approved the Company’s modular premarket approval application (PMA) pathway for FemBloc, its investigational non-surgical permanent birth control technology in the United States. FemBloc is approved for marketing in Europe and other select international markets. "FDA approval of the modular PMA pathway provides a clear and efficient framework for a
- SECSEC Form 10-Q filed by Femasys Inc.10-Q - FEMASYS INC (0001339005) (Filer)
- PRFemasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the FemBloc® clinical and regulatory program toward U.S. approval -- ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update. Corporate Highlights from 2Q 2026 to date Completed $30 million private placement with potential proceeds of up t
- PRFemasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today the issuance of patents in the United States and key international markets that expand intellectual property protection for the blended polymer component of FemBloc, the Company’s non-surgical permanent birth control technology. These patents broaden and ex
- INSIDERSEC Form 4 filed by Director Eichenbaum Kenneth D.4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Director Uzialko Edward R4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Director Milnes Alistair4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Director Larsen Charles4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERChief Clinical-Medical Affairs Mifek Jeffrey Gerald bought $10,000 worth of shares (3,125 units at $3.20) (SEC Form 4)4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Chief Clinical-Medical Affairs Mifek Jeffrey Gerald4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERNew insider Mifek Jeffrey Gerald claimed ownership of 1,411 shares (SEC Form 3)3 - FEMASYS INC (0001339005) (Issuer)
- INSIDERChief Technology Officer Sipos Jeremy Alexander bought $10,000 worth of shares (3,125 units at $3.20) (SEC Form 4)4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERChief Operating Officer Canning John Charles bought $14,000 worth of shares (4,375 units at $3.20) (SEC Form 4)4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERChief Financial Officer Elefant Dov bought $50,000 worth of shares (15,625 units at $3.20) (SEC Form 4)4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERChief Executive Officer Lee-Sepsick Kathy bought $50,000 worth of shares (15,625 units at $3.20) (SEC Form 4)4 - FEMASYS INC (0001339005) (Issuer)
- SECFemasys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - FEMASYS INC (0001339005) (Filer)
- PRFemasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million-- Potential proceeds would be received upon full cash exercise of warrants -- ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has entered into a securities purchase agreement (the "Purchase Agreement") for a $30 million private placement with certain accredited investors. The financing was led by new institutional investor Nantahala Capital, with participation from additional new healthcare-focused funds, including Rosalind Advisor
- SECFemasys Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - FEMASYS INC (0001339005) (Filer)
- SECFemasys Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - FEMASYS INC (0001339005) (Filer)
- PRFemasys Regains Compliance with Nasdaq Listing RequirementsATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today that it received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained compliance with Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing and that the matter is now closed. Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys, stated, "Regaining compliance with Nasdaq’s continued listing requirements is an important development for Femasys and our shareholders. With th
- SECFemasys Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - FEMASYS INC (0001339005) (Filer)
- SECFemasys Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - FEMASYS INC (0001339005) (Filer)
- SECFemasys Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - FEMASYS INC (0001339005) (Filer)
- PRFemasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ CatheterATLANTA, May 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today CE Mark approval for its FemHSG™ Catheter, further expanding the Company's portfolio in Europe through commercial partners. Designed to support procedural efficiency during the initial fertility workup, the FemHSG Catheter is used together with the Company's FemVue device for in-office ultrasound-based evaluation. Infertility impacts millions of women worldwide, and because appropriate diagnosis is essential prior to treatment, Femasys is focused on e
FEMY FAQ
7 questionsWhat does Femasys Inc. do?
Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its...Where does FEMY stock trade?
Femasys Inc. (FEMY) is listed on NASDAQ.What sector and industry is FEMY in?
Femasys Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Femasys Inc. go public?
Femasys Inc. (FEMY) completed its IPO in 2021.What are analysts saying about FEMY?
Femasys Inc. has had 3 recent analyst actions on file. The most recent action was from Laidlaw: Buy with a $650.00 price target on 2025-11-20. Recent price targets range from $650.00 to $2500.00.What companies are similar to FEMY?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare FEMY side-by-side with any of them on Quantisnow.How can I track FEMY on Quantisnow?
Quantisnow aggregates Femasys Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FEMY to receive live email and push alerts on every new disclosure.